Prediction Score for Anticoagulation Control Quality Among Older Adults
Why the study?
Does the PROSPER score improve prediction of TTR ≥70% compared to the SAMe-TT2R2 score in older adults taking vitamin K antagonists?
Population
2,844 patients aged ≥65 years taking vitamin K antagonists for nonvalvular atrial fibrillation or venous…
Comparison
PROSPER score vs SAMe-TT2R2 score
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
May aid VKA selection in older adults; leaves open whether model use improves clinical outcomes.
Structured PICO
Does the PROSPER score improve prediction of TTR ≥70% compared to the SAMe-TT2R2 score in older adults taking vitamin K antagonists?
P
Population
2,844 patients aged ≥65 years taking vitamin K antagonists for nonvalvular atrial fibrillation or venous thromboembolism, identified in 2 US electronic health record databases linked with Medicare claims data from 2007 through 2014.
I
Intervention
PROSPER score (a 7-variable prediction model for Time in Therapeutic Range)
C
Comparator
SAMe-TT2R2 score
O
Outcome
Prediction of Time in Therapeutic Range (TTR) ≥70% and thromboembolic and bleeding outcomessurrogate
The PROSPER score outperforms the SAMe-TT2R2 score in predicting anticoagulation control quality and clinical outcomes in older adults on vitamin K antagonist therapy.
Cite This Study
Lin et al. (2017) studied this question.